Scholar Rock Holding (STU:2QK) Land And Improvements : €0.00 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Scholar Rock Holding Land And Improvements?

Scholar Rock Holding's land and improvements for the quarter that ended in Mar. 2024 was €0.00 Mil.

Scholar Rock Holding Land And Improvements Historical Data

The historical data trend for Scholar Rock Holding's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scholar Rock Holding Land And Improvements Chart

Scholar Rock Holding Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Land And Improvements

Get a 7-Day Free Trial

Scholar Rock Holding Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Land And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

Scholar Rock Holding Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Scholar Rock Holding (STU:2QK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scholar Rock Holding Corp (STU:2QK) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

SRRK:USA

Address

301 Binney Street, 3rd Floor, Cambridge, MA, USA, 02142

Website

https://www.scholarrock.com

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States. The company's lead product candidate is Apitegroma which is a highly selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGF?1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

Scholar Rock Holding (STU:2QK) Headlines

No Headlines